Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic acid or denosumab for back pain with Modic changes
ACTRN12614000719639Phase 3Completed
- Sponsor
- University of Tasmania
- Start
- Nov 2014
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Dorsalgia and Modic changes (MC) comparing Zoledronic acid, Denosumab and Placebo (3 arms). Primary endpoints: Back pain and Maximum size of Modic lesion. Started Nov 2014; status: completed.
02
Drugs
zoledronic aciddenosumab
03
Conditions
DorsalgiaModic changes (MC)
Beyond the preview
Go deeper on ACTRN12614000719639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614000719639.